Intensive chemotherapy for elderly patients with acute myelogeneous leukemia: A propensity score analysis by the Japan Hematology and Oncology Clinical Study Group (J-HOCS)

Annals of Hematology

Volumn 91, Issue 10, 2012, Pages 1533-1539

  Oshima, Kumi ^a   Takahashi, Wataru ^b   Asano Mori, Yuki ^c   Izutsu, Koji ^d   Takahashi, Tsuyoshi ^e   Arai, Yukihiro ^b   Nakagawa, Yasunori ^c   Usuki, Kensuke ^d   Kurokawa, Mineo ^e   Suzuki, Kenshi ^c   Mitani, Kinuko ^b   Kanda, Yoshinobu ^a  

^a JICHI MEDICAL UNIVERSITY   (Japan)

^b DOKKYO MEDICAL UNIVERSITY   (Japan)

^c JAPANESE RED CROSS MEDICAL CENTER   (Japan)

^d Kanto Teishin Hospital   (Japan)

^e UNIVERSITY OF TOKYO HOSPITAL   (Japan)

Author keywords

AML; Elderly; Intensive chemotherapy; Propensity score

Indexed keywords

CYTARABINE; DAUNORUBICIN; ENOCITABINE; IDARUBICIN; MITOXANTRONE;

ACUTE GRANULOCYTIC LEUKEMIA; AGED; ARTICLE; CANCER COMBINATION CHEMOTHERAPY; CANCER SURVIVAL; CLINICAL EVALUATION; DOSE RESPONSE; FEMALE; GERIATRIC CARE; GERIATRIC PATIENT; HUMAN; INDUCTION CHEMOTHERAPY; LOW DRUG DOSE; MAJOR CLINICAL STUDY; MALE; OUTCOME ASSESSMENT; OVERALL SURVIVAL; PRIORITY JOURNAL; PROMYELOCYTIC LEUKEMIA; PROPENSITY SCORE; RETROSPECTIVE STUDY;

AGED; AGED, 80 AND OVER; ANTINEOPLASTIC COMBINED CHEMOTHERAPY PROTOCOLS; FEMALE; HUMANS; JAPAN; LEUKEMIA, MYELOID, ACUTE; MALE; PROPENSITY SCORE; RETROSPECTIVE STUDIES; SURVIVAL RATE;

EID: 84867329836     PISSN: 09395555     EISSN: 14320584     Source Type: Journal    
DOI: 10.1007/s00277-012-1487-1     Document Type: Article

References (17)

1. Brincker H (1982) Population-based age- and sex-specific incidence rates in the 4 main types of leukaemia. Scand J Haematol 29:241-249
2. Ferrara F, Pinto A (2007) Acute myeloid leukemia in the elderly: current therapeutic results and perspectives for clinical research. Rev Recent Clin Trials 2:33-41
3. Bassan R, Buelli M, Viero P, Minotti C, Barbui T (1992) The management of acute myelogenous leukemia in the elderly: tenyear experience in 118 patients. Hematol Oncol 10:251-260
4. Dohner H, Estey EH, Amadori S, Appelbaum FR, Buchner T, Burnett AK, Dombret H, Fenaux P, Grimwade D, Larson RA, Lo-Coco F, Naoe T, Niederwieser D, Ossenkoppele GJ, Sanz MA, Sierra J, Tallman MS, Lowenberg B, Bloomfield CD (2010) Diagnosis and management of acute myeloid leukemia in adults: recommendations from an international expert panel, on behalf of the European LeukemiaNet. Blood 115:453-474
5. Juliusson G, Antunovic P, Derolf A, Lehmann S, Mollgard L, Stockelberg D, Tidefelt U, Wahlin A, Hoglund M (2009) Age and acute myeloid leukemia: real world data on decision to treat and outcomes from the Swedish Acute Leukemia Registry. Blood 113:4179-4187
6. Djunic I, Virijevic M, Novkovic A, Djurasinovic V, Colovic N, Vidovic A, Suvajdzic-Vukovic N, Tomin D (2011) Comorbidity as a risk factor for overall survival and decision criteria for intensity of chemotherapy in elderly patients with acute myeloid leukemia. Med Oncol
7. Estey EH (2011) Treatment of acute myeloid leukemia in the elderly. Haematologica 96:795-798
8. Ziogas DC, Voulgarelis M, Zintzaras E (2011) A network metaanalysis of randomized controlled trials of induction treatments in acute myeloid leukemia in the elderly. Clin Ther 33:254-279
9. Montamat SC, Cusack B, Vestal RE (1989) Management of drug therapy in the elderly. N Engl J Med 321:303-309
10. Lee SG, Park TS, Oh SH, Park JC, Yang YJ, Marschalek R, Meyer C, Cho EH, Shin SY (2011) De novo acute myeloid leukemia associated with t(11;17)(q23;q25) and MLL-SEPT9 rearrangement in an elderly patient: a case study and review of the literature. Acta Haematol 126:195-198
11. Perrot A, Luquet I, Pigneux A, Mugneret F, Delaunay J, Harousseau JL, Barin C, Cahn JY, Guardiola P, Himberlin C, Recher C, Vey N, Lioure B, Ojeda-Uribe M, Fegueux N, Berthou C, Randriamalala E, Bene MC, Ifrah N,Witz F (2011) Dismal prognostic value of monosomal karyotype in elderly patients with acute myeloid leukemia: a GOELAMS study of 186 patients with unfavorable cytogenetic abnormalities. Blood 118:679-685
12. Giles FJ, Borthakur G, Ravandi F, Faderl S, Verstovsek S, Thomas D, Wierda W, Ferrajoli A, Kornblau S, Pierce S, Albitar M, Cortes J, Kantarjian H (2007) The haematopoietic cell transplantation comorbidity index score is predictive of early death and survival in patients over 60 years of age receiving induction therapy for acute myeloid leukaemia. Br J Haematol 136:624-627
13. Rosenbaum PR, Rubin DB (1983) The central role of the propensity score in observational studies for causal effects. Biometrika 70:41-55
14. Teng EL, Hasegawa K, Homma A, Imai Y, Larson E, Graves A, Sugimoto K, Yamaguchi T, Sasaki H, Chiu D et al (1994) The cognitive abilities screening instrument (CASI): a practical test for cross-cultural epidemiological studies of dementia. Int Psychogeriatr 6:45-58, discussion 62
15. Satariano WA, Ragland D (1994) The effect of comorbidity on 3-year survival of women with primary breast cancer. Ann Intern Med 120:104-110
16. Lowenberg B, Zittoun R, Kerkhofs H, Jehn U, Abels J, Debusscher L, Cauchie C, Peetermans M, Solbu G, Suciu S et al (1989) On the value of intensive remission-induction chemotherapy in elderly patients of 65+ years with acute myeloid leukemia: a randomized phase III study of the European Organization for Research and Treatment of Cancer Leukemia Group. J Clin Oncol 7:1268-1274
17. Tilly H, Castaigne S, Bordessoule D, Casassus P, Le Prise PY, Tertian G, Desablens B, Henry-Amar M, Degos L (1990) Low-dose cytarabine versus intensive chemotherapy in the treatment of acute nonlymphocytic leukemia in the elderly. J Clin Oncol 8:272-279